The company's outlook considers the expected impact on pricing as the acetyls market absorbs the industry capacity expansions planned for the second half of 2005. The company has now included the expected positive impact of the recently completed Acetex acquisition in its forecasts for 2005. Previous company guidance for the year was between $1.64 and $1.69 per share and did not include any impact from Acetex.

"While the Acetex acquisition is accretive in the second half of 2005, the bulk of the increase in our guidance is due to the ongoing strength of our businesses," said Weidman.

Adjusted EBITDA is expected to be between $240 million and $260 million for the third quarter and between $1,060 million and $1,090 million for the full year, an increase from the $960 million to $1,000 million forecasted previously.

Forward-Looking Statements

This release may contain "forward-looking statements," which include information concerning the company's plans, objectives, goals, strategies, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. When used in this release, the words "estimates," "expects," "anticipates," "projects," "plans," "intends," "believes," and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the company will realize these expectations or that these beliefs will prove correct.

There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained in this release. Numerous factors, many of which are beyond the company's control, could cause actual results to differ materially from those expressed as forward-looking statements. Certain of these risk factors are discussed in the company's Annual Report on Form 10K. Any forward-looking statement speaks only as of the date on which it is made, and the company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.

Successor

Successor represents Celanese Corporation's financial position as of June 30, 2005 and December 31, 2004 and its consolidated results of operations for the three months and six months ended June 30, 2005 and three months ended June 30, 2004. These consolidated financial statements reflect the application of purchase accounting relating to the acquisition of Celanese AG and preliminary purchase accounting adjustments relating to the acquisition of Vinamul.

Predecessor

Predecessor represents Celanese AG's consolidated results of its operations for the three months ended March 31, 2004. These results relate to a period prior to the acquisition of Celanese AG and present Celanese AG's historical basis of accounting without the application of purchase accounting.

The results of the Successor are not comparable to the results of the Predecessor due to the difference in the basis of presentation of purchase accounting as compared to historical cost and different accounting policies.

Reconciliation of Non-U.S. GAAP Measures to U.S. GAAP

This release reflects three performance measures, net debt, adjusted EBITDA, and diluted adjusted earnings per share as non-U.S. GAAP measures. The most directly comparable financial measure presented in accordance with U.S. GAAP in our consolidated financial statements for net debt is total debt; for adjusted EBITDA is net earnings (loss); and for diluted adjusted earnings per share is diluted earnings (loss) per share. For a reconciliation of these non-U.S. GAAP measures to U.S. GAAP figures, see the accompanying schedules to this release.

4

Use of Non-U.S. GAAP Financial Information

Adjusted EBITDA, a measure used by management to measure performance, is defined as earnings (loss) from continuing operations, plus interest expense net of interest income, income taxes and depreciation and amortization, and further adjusted for certain cash and non-cash charges. Our management believes adjusted EBITDA is useful to investors because it is one of the primary measures our management uses for its planning and budgeting processes and to monitor and evaluate financial and operating results. Adjusted EBITDA is not a recognized term under U.S. GAAP and does not purport to be an alternative to net earnings as a measure of operating performance or to cash flows from operating activities as a measure of liquidity. Because not all companies use identical calculations, this presentation of adjusted EBITDA may not be comparable to other similarly titled measures of other companies. Additionally, adjusted EBITDA is not intended to be a measure of free cash flow for management's discretionary use, as it does not consider certain cash requirements such as interest payments, tax payments and debt service requirements nor does it represent the amount used in our debt covenants. Net debt is defined as total debt less cash and cash equivalents. Our management uses net debt to evaluate the Company's capital structure. Diluted adjusted net earnings per share is defined as income available to common shareholders plus preferred dividends, adjusted for special and one-time expenses and divided by the number of basic common and diluted preferred shares outstanding as of June 30, 2005. We believe that the presentation of all of the non-U.S. GAAP information provides useful information to management and investors regarding various financial and business trends relating to our financial condition and results of operations, and that when U.S. GAAP information is viewed in conjunction with non-U.S. GAAP information, investors are provided with a more meaningful understanding of our ongoing operating performance. This non-U.S. GAAP information is not intended to be considered in isolation or as a substitute for U.S. GAAP financial information.

Results Unaudited: The results presented in this release, together with the adjustments made to present the results on a comparable basis, have not been audited and are based on internal financial data furnished to management. Quarterly results should not be taken as an indication of the results of operations to be reported for any subsequent period or for the full fiscal year.

5

---

Consolidated Statements of Operations

				Q2 2005				Q2 2004				6M 2005				6M 2004
in $ millions				Successor				Successor				Successor				Combined
Net sales					1,517				1,229				3,026				2,472
Cost of sales					(1,175	)			(1,058	)			(2,300	)			(2,060	)
Gross profit					342				171				726				412
Selling, general and administrative expense					(136	)			(125	)			(297	)			(262	)
Research and development expense					(23	)			(22	)			(46	)			(45	)
Special charges:
Insurance recoveries associated with plumbing cases					4				2				4				2
Restructuring, impairment and other special charges					(31	)			(1	)			(69	)			(29	)
Foreign exchange gain (loss), net					(1	)			—				2				—
Loss on disposition of assets					(3	)			—				(2	)			(1	)
Operating profit					152				25				318				77
Equity in net earnings of affiliates					12				18				27				30
Interest expense					(68	)			(130	)			(244	)			(136	)
Interest income					9				7				24				12
Other income (expense), net					18				(24	)			21				(15	)
Earnings (loss) from continuing operations before tax and minority interests					123				(104	)			146				(32	)
Income tax provision					(43	)			(10	)			(51	)			(27	)
Earnings (loss) from continuing operations before minority interests					80				(114	)			95				(59	)
Minority interests					(13	)			(10	)			(38	)			(10	)
Earnings (loss) from continuing operations					67				(124	)			57				(69	)
Earnings (loss) from operation of discontinued operations (including gain on disposal of discontinued operations)					—				(1	)			—				8
Related income tax benefit					—				—				—				14
Earnings (loss) from discontinued operations					—				(1	)			—				22
Net earnings (loss)					67				(125	)			57				(47	)

6

---

Consolidated Balance Sheets

in $ millions				June 30 2005				Dec 31 2004
ASSETS
Current assets:
Cash and cash equivalents					959				838
Receivables, net:
Trade receivables, net - third party and affiliates					955				866
Other receivables					523				670
Inventories					586				618
Deferred income taxes					75				71
Other assets					106				86
Assets of discontinued operations					3				2
Total current assets					3,207				3,151
Investments					543				600
Property, plant and equipment, net					1,756				1,702
Deferred income taxes					36				54
Other assets					652				756
Goodwill					813				747
Intangible assets, net					389				400
Total assets					7,396				7,410
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
Current liabilities:
Short-term borrowings and current installments of long-term debt					140				144
Accounts payable and accrued liabilities:
Trade payables - third party and affiliates					682				722
Other current liabilities					739				888
Deferred income taxes					14				20
Income taxes payable					230				214
Liabilities of discontinued operations					7				7
Total current liabilities					1,812				1,995
Long-term debt					3,253				3,243
Deferred income taxes					227				256
Benefit obligations					1,003				1,000
Other liabilities					452				510
Minority interests					523				518
Shareholders' equity (deficit):
Preferred stock					—				—
Common stock					—				—
Additional paid-in capital					350				158
Retained earnings (deficit)					(196	)			(253	)
Accumulated other comprehensive loss					(28	)			(17	)
Shareholders' equity (deficit)					126				(112	)
Total liabilities and shareholders' equity (deficit)					7,396				7,410

7

---

SALES

Table 1

Net Sales

				Q2 2005				Q2 2004				6M 2005				6M 2004
in $ millions				Successor				Successor				Successor				Combined
Chemical Products					1,085				808				2,129				1,626
Technical Polymers Ticona					223				220				462				447
Acetate Products					183				173				379				345
Performance Products					47				45				94				89
Segment total					1,538				1,246				3,064				2,507
Other activities					8				11				20				22
Intersegment eliminations					(29	)			(28	)			(58	)			(57	)
Total					1,517				1,229				3,026				2,472

Table 2

Factors Affecting Second Quarter 2005 Segment Sales Compared to Second Quarter 2004

in percent				Volume				Price				Currency				Other*				Total
Chemical Products					–1	%			21	%			2	%			12	%			34	%
Technical Polymers Ticona					–5	%			4	%			2	%			0	%			1	%
Acetate Products					1	%			5	%			0	%			0	%			6	%
Performance Products					2	%			–3	%			5	%			0	%			4	%
Segment total					–2	%			15	%			2	%			8	%			23	%

*	Primarily represents sales of the recently acquired Vinamul emulsion business

Table 3

Factors Affecting Six Months 2005 Segment Sales Compared to Six Months 2004

in percent				Volume				Price				Currency				Other*				Total
Chemical Products					–1	%			21	%			3	%			8	%			31	%
Technical Polymers Ticona					–1	%			2	%			2	%			0	%			3	%
Acetate Products					6	%			4	%			0	%			0	%			10	%
Performance Products					5	%			–5	%			6	%			0	%			6	%
Segment total					0	%			15	%			2	%			5	%			22	%

*	Primarily represents sales of the recently acquired Vinamul emulsion business

8

---

KEY FINANCIAL DATA

Table 4

Operating Profit (Loss)

				Q2 2005				Q2 2004				6M 2005				6M 2004
in $ millions				Successor				Successor				Successor				Combined
Chemical Products					155				36				332				101
Technical Polymers Ticona					5				11				44				42
Acetate Products					10				10				30				19
Performance Products					15				2				28				13
Segment total					185				59				434				175
Other activities					(33	)			(34	)			(116	)			(98	)
Total					152				25				318				77

Table 5

Earnings (Loss) from Continuing Operations Before Tax and Minority Interests

				Q2 2005				Q2 2004				6M 2005				6M 2004
in $ millions				Successor				Successor				Successor				Combined
Chemical Products					149				34				342				98
Technical Polymers Ticona					22				26				73				71
Acetate Products					12				14				32				23
Performance Products					14				1				26				12
Segment total					197				75				473				204
Other activities					(74	)			(179	)			(327	)			(236	)
Total					123				(104	)			146				(32	)

Table 6

Depreciation and Amortization Expense

				Q2 2005				Q2 2004				6M 2005				6M 2004
in $ millions				Successor				Successor				Successor				Combined
Chemical Products					39				38				73				77
Technical Polymers Ticona					14				15				29				31
Acetate Products					9				14				18				27
Performance Products					3				2				6				4
Segment total					65				69				126				139
Other activities					2				2				4				4
Total					67				71				130				143

9

---

KEY FINANCIAL DATA - (continued)

Table 7

Cash Dividends Received

				Q2 2005				Q2 2004				6M 2005				6M 2004
in $ millions				Successor				Successor				Successor				Combined
Dividends from equity investments					10				6				46				21
Other distributions from equity investments					—				—				—				1
Dividends from cost investments					7				7				21				13
Total					17				13				67				35

SPECIAL CHARGES AND OTHER EXPENSES

Table 8

Special Charges in Operating Profit (Loss)

				Q2 2005				Q2 2004				6M 2005				6M 2004
in $ millions				Successor				Successor				Successor				Combined
Chemical Products					(3	)			(1	)			(4	)			(2	)
Technical Polymers Ticona					(20	)			2				(21	)			1
Acetate Products					—				—				(1	)			—
Performance Products					—				—				—				—
Segment total					(23	)			1				(26	)			(1	)
Other activities					(4	)			—				(39	)			(26	)
Total					(27	)			1				(65	)			(27	)

Table 9

Breakout of Special Charges by Type

				Q2 2005				Q2 2004				6M 2005				6M 2004
in $ millions				Successor				Successor				Successor				Combined
Employee termination benefits					(7	)			(1	)			(9	)			(3	)
Plant/office closures					—				—				(1	)			—
Total restructuring					(7	)			(1	)			(10	)			(3	)
Insurance recoveries associated with plumbing cases					4				2				4				2
Asset impairments					(24	)			—				(24	)			—
Termination of advisor monitoring services					—				—				(35	)			—
Advisory services					—				—				—				(25	)
Other					—				—				—				(1	)
Total					(27	)			1				(65	)			(27	)

10

---

RECONCILATION OF NON-US GAAP ITEMS

Table 10

Earnings Per Share

in $ millions, except for share and per share data				Q2 2005 Actual				Q2 2005 Adjusted
Earnings from continuing operations before tax and minority interests					123				123
Adjustments:
Favorable impact on non-operating foreign exchange position					—				(14	)
Special charges					—				27
Earnings from continuing operations before tax and minority interests					123				136
Income tax provision*					(43	)			(33	)
Minority interests					(13	)			(13	)
Preferred dividends					(2	)			(2	)
Net earnings available to common shareholders					65				88
Basic EPS Calculation
Weighted average shares outstanding (thousands)					158,530				—
Basic EPS					0.41				—
Diluted EPS Calculation
Net earnings available to common shareholders					65				88
Add back: Preferred dividends					2				2
Net earnings for diluted EPS					67				90
Diluted shares (thousands)
Weighted average shares outstanding					158,530				158,530
Conversion of Preferred Shares					12,000				12,000
Assumed conversion of stock options					—				—
Total diluted shares					170,530				170,530
Diluted EPS					0.39				0.53

*	Effective tax rate for Adjusted EPS is 24% and for Actual EPS is 35%

Table 11

Net Debt

in $ millions				June 30 2005				Dec 31 2004
Short-term borrowings and current installments of long-term debt					140				144
Plus: Long-term debt					3,253				3,243
Total debt					3,393				3,387
Less: Cash and cash equivalents					959				838
Net Debt					2,434				2,549

11

---

Table 12

Adjusted EBITDA

in $ millions				Q2 2005				Q2 2004				6M 2005
Net earnings (loss)					67				(125	)			57
(Earnings) loss from discontinued operations					—				1				—
Interest expense					68				130				244
Interest income					(9	)			(7	)			(24	)
Income tax provision					43				10				51
Depreciation and amortization					67				71				130
EBITDA					236				80				458
Adjustments:
Cash dividends received in excess of equity in net earnings of affiliates					(2	)			(12	)			19
Special charges					27				(1	)			65
Other unusual items and adjustments (1)					22				121				75
Adjusted EBITDA					283				188				617

(1)	Other Unusual Items and Adjustments

in $ millions				Q2 2005				Q2 2004				6M 2005
Net (gain) loss on disposition of assets					3				—				2
Excess of minority interest income over cash dividends paid to minority shareholders					13				9				38
Severance and other restructuring charges not included in special charges					—				9				2
Cash interest income used by captive insurance subsidiaries to fund operations					3				2				6
Franchise taxes					1				1				1
Unusual and non-recurring items*					6				40				15
Non-cash charges**					(4	)			50				1
Advisor monitoring fee					—				2				10
Pro forma cost savings***					—				8				—
Total Other Unusual Items and Adjustments					22				121				75

*	Primarily includes costs related to the Celanese AG (Q2 2004) and Vinamul acquisition (Q2 2005 and 6M 2005), productivity enhancement programs (all periods presented), Summit (all periods presented) and Bedminster relocations (Q2 2005 and 6M 2005), and IPO bonus (6M 2005).

**	Primarily includes ineffective portion of a net investment hedge (Q2 2005 and 6M 2005) and purchase accounting adjustment for inventories (Q2 2004).

***	Primarily represents adjustments on a proforma basis for certain cost savings that we expect to achieve from additional pension contributions (Q2 2004).

12

---

Table 13

Guidance Diluted Adjusted EPS

in $ millions, except for share and per share data				Q3 2005 Mid- Point Guidance Diluted EPS				Q3 2005 Mid- Point Guidance Diluted Adj. EPS				FY 2005 Mid- Point Guidance Diluted EPS				FY 2005 Mid- Point Guidance Diluted Adj. EPS
Earnings from continuing operations before tax and minority interests					92				92				299				299
Adjustments:
Monitor Fee					—				—				—				10
Refinancing costs					—				15				—				117
Favorable impact on non-operating foreign exchange position					—				—				—				(14	)
Special charges					—				15				—				105
Earnings from continuing operations before tax and minority interests					92				122				299				517
Income tax provision					(32	)			(29	)			(105	)			(124	)
Minority interest					(12	)			(12	)			(60	)			(60	)
Preferred dividends					(2	)			(2	)			(10	)			(10	)
Net earnings available to common shareholders					46				79				124				323
Basic EPS Calculation
Weighted average shares outstanding (thousands)					158,530				—				158,530				—
Basic EPS					0.29				—				0.78				—
Diluted EPS Calculation
Net earnings available to common shareholders					46				79				124				323
Add back: Preferred dividends					2				2				10				10
Net earnings for diluted EPS					48				81				134				333
Diluted shares (thousands)
Weighted average shares outstanding					158,530				158,530				158,530				158,530
Conversion of Preferred Shares					12,000				12,000				12,000				12,000
Assumed conversion of stock options					—				—				—				—
Total diluted shares					170,530				170,530				170,530				170,530
Diluted EPS					0.28				0.47				0.79				1.95

13

---

Table 14

Guidance Adjusted EBITDA

in $ millions				Guidance Q3 2005				Guidance FY 2005
Net earnings (loss)					48				134
(Earnings) loss from discontinued operations					—				—
Interest expense					90				412
Interest income					(5	)			(34	)
Income tax provision (benefit)					32				105
Depreciation and amortization					66				252
EBITDA					231				869
Adjustments:
Cash dividends received in excess of equity in net earnings of affiliates					(7	)			(4	)
Special charges					15				105
Other unusual items and adjustments *					11				105
Adjusted EBITDA					250				1,075

*	Primarily includes the following:

Excess of minority interest income over cash dividends paid to minority shareholders

Severance and other restructuring charges not included in special charges

Cash interest income used by captive insurance subsidiaries to fund operations

Unusual and non-recurring items

Advisor monitoring fee

Other minor items

14

---